康哲药业：磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症新药上市许可申请获受理

Core Viewpoint - Kangzheng Pharmaceutical announced that its subsidiary, Demy Pharmaceutical, has received acceptance from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of phospholipase A2 cream for the treatment of mild to moderate atopic dermatitis (AD) [1] Group 1 - The product is intended for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in children aged 2 years and older and adults with non-impaired immune function when other topical medications are poorly controlled or not recommended [1] - The acceptance of the NDA for the AD indication marks a key milestone for the product's expansion into multiple therapeutic areas [1]